A/Prof Annette Lim
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
80 Scholarly works
2 Projects
HIGHLIGHTS
2026
Journal article
Immunotherapy response and resistance in cutaneous squamous cell carcinoma
DOI: 10.20935/acadonco83392026
Journal article
C-POST study of adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma (CSCC): Disease-free survival (DFS) analyses per high-risk criteria and per start time after radiotherapy.
DOI: 10.1200/jco.2026.44.16_suppl.60832026
Journal article
Clinical and Patient-Reported Outcomes (PROs) in C-POST: Phase 3 Trial of Adjuvant Cemiplimab (Cemi) vs Placebo (Pbo) for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
DOI: 10.1016/j.ijrobp.2026.02.1432026
Journal article
Abstract CT240: IOB-032/PN-E40: A phase 2 study of neoadjuvant/adjuvant IO102-IO103 cancer vaccine plus pembrolizumab in resectable HNSCC
DOI: 10.1158/1538-7445.am2026-ct2402026
Journal article
Extended follow-up outcomes of patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab on EMPOWER-CSCC-1: A retrospective cohort study
DOI: 10.1016/j.jaad.2025.11.0802025
Research grants (ARC, NHMRC, MRFF)
Defining Immunotherapy Response and Resistance Mechanisms in Cutaneous Squamous Cell Carcinoma.
2022
Research grants (ARC, NHMRC, MRFF)
Understanding Response and Resistance to Immunotherapy in Immunocompromised Patients With Cutaneous Squamous Cell Carcinomas
RECENT SCHOLARLY WORKS
2026
Journal article
Adjuvant nivolumab for resected high-risk head and neck cancer
DOI: 10.1016/S0140-6736(26)00133-92026
Journal article
A Multicentre, Open-Label, Phase 2 Study of Intratumoural Toll-Like Receptor 9 Agonist Vidutolimod in Combination with Intravenous Cemiplimab in Advanced or Metastatic Non-Melanoma Skin Cancers: Clinical Results
DOI: 10.1016/j.ejcskn.2026.1009442025
Journal article
Evaluating CD103 intratumoral immune cell abundance and PD-L1 CPS in primary tumors versus lymph nodes in Human papillomavirus associated oropharyngeal Cancer
DOI: 10.1016/j.oraloncology.2025.1077922025
Journal article
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors
DOI: 10.1136/jitc-2025-0118652025
Journal article
1324MO ASPEN-04: A randomized phase II study of evorpacept in combination with pembrolizumab and chemotherapy in patients with recurrent, unresectable or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
DOI: 10.1016/j.annonc.2025.08.1956